富士フイルムホールディングス株式会社 · FY2026

Is Fujifilm really a photography company?

The word 'film' is still in Fujifilm's name. Yet in FY2026, Imaging accounted for less than one-fifth of group revenue. Business Innovation was the largest segment, while Healthcare exceeded ¥1 trillion. Photography has not disappeared, however. The more revealing story is how technologies accumulated for photographic film were inventoried and carried into medical systems, biopharmaceutical manufacturing and semiconductor materials.

18.7%Imaging share of group revenue (site calculation)
¥1.099tnHealthcare revenue
12 / 16 unitsNew U.S. Bio CDMO units sold before operation

This is not investment advice or a stock recommendation. We reorder company-published primary-source facts to make the shape of the business easier to see.

Fujifilm’s name still tells you exactly where the company came from.

Photographic film. Cameras. That remains a natural first impression.

But split today’s revenue into four businesses and the company starts to look very different from its name.

First, revenue is ¥3.357 trillion

The scale alone does not tell us whether this is still a photography company.

The segment mix does.

Imaging is 18.7% of revenue

DATA VIEW

Imaging is less than one-fifth of group revenue

FY2026. Site calculation dividing segment revenue by consolidated revenue.

Revenue mix: Imaging 18.7%, Other three segments 81.3%Revenue mix
Imaging18.7%Other three segments81.3%

Does that make photography a small legacy business?

Not quite.

Imaging still produced ¥160.0 billion of operating income

Fujifilm did not simply leave photography behind.

It kept a strong Imaging business while building even larger businesses around it.

Healthcare is already above ¥1 trillion

DATA VIEW

Today's Fujifilm is built from four large businesses

FY2026 segment revenue.

¥1.175tnBusiness Innovation
¥1.099tnHealthcare
¥627.1bnImaging
¥456.2bnElectronics

Medical systems, outsourced biopharmaceutical manufacturing, semiconductor materials.

Why do businesses that seem so far from film sit inside the same group?

When film demand collapsed, Fujifilm made a “technology inventory”

The company was not starting from zero.

It was breaking down what it had learned to do for photography and asking where else those capabilities could work.

One photograph required chemistry, thin films, imaging and precision processing

From this angle, healthcare and semiconductors no longer look like disconnected side businesses.

Healthcare, for example, expanded beyond selling equipment into manufacturing other companies’ drugs.

Fujifilm entered Bio CDMO at scale in 2011

That business has reached the point where customers are reserving large-scale production capacity before the equipment even begins operating.

Twelve of sixteen new U.S. units were sold before operation

That is a very different investment picture from a traditional photo company.

The other major growth field is semiconductor materials.

Fujifilm says its CMP slurry is No.1 for copper-wire applications

As AI and HBM make semiconductors more complex, the number of wiring layers and polishing steps increases.

Fujifilm wants to turn that materials position into a much larger business.

The FY2030 semiconductor-materials revenue target is ¥500 billion

At this point it is tempting to say Fujifilm is no longer a photography company.

But that misses part of the story.

Imaging still generated ¥627.1 billion of FY2026 revenue and ¥160.0 billion of operating income. Photography and cameras did not disappear; they remain a profitable business.

What changed is where the technologies learned through photography can be used.

THE VIEW AFTER THE NUMBERS

What the numbers suggest

Connect the numbers and Fujifilm looks less like a photo company that escaped into healthcare and semiconductors and more like a company that repeatedly moved technologies built for photography into new industries.

Imaging is down to 18.7% of group revenue, yet it still produced ¥160.0 billion of operating income. Around it now sit ¥1.099 trillion of Healthcare revenue and ¥456.2 billion of Electronics revenue. When film demand collapsed in the 2000s, Fujifilm explicitly inventoried the technologies it had accumulated and applied them to new growth fields.

That path now reaches large-scale Bio CDMO facilities and a No.1 company-disclosed position in CMP slurry for copper wiring. The “film” left in Fujifilm’s name is not merely a reminder of an old business. It is the starting point of the technology base that still connects the group today.

Primary sources used

Earnings Presentation for the Fiscal Year Ended March 2026

FUJIFILM Holdings Corporation · 2026-05-12

Pages used: p.10

Open source →

Integrated Report 2025

FUJIFILM Holdings Corporation

Pages used: p.13 / p.16

Open source →

Semiconductor Materials Business Briefing

FUJIFILM Holdings Corporation · 2025-12-10

Pages used: p.35 / p.51

Open source →

Bio CDMO Business Briefing

FUJIFILM Holdings Corporation · 2026-02-19

Pages used: p.23

Open source →

NEXT COMPANY

味の素株式会社 · FY2026

Look at the next company

Is Ajinomoto really a seasoning company?

Ajinomoto has not stopped being a food company. It has repeatedly extended fermentation, synthesis and formulation capabilities built around food into healthcare and electronic materials. Seasoning and AI semiconductors look far apart, but the primary sources reveal a long continuity in how the company develops technology.

See the company through the numbers →
77.5%Sales from seasonings & foods plus frozen foods